Home/Research library/Sikiric et al. (2011)
Review · 2011 · cited for BPC-157

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Current pharmaceutical design 2011;17(16):1612-32. doi:10.2174/138161211796196954 · PubMed 21548867

In brief

This review presents BPC 157, a fifteen-residue fragment (GEPPPGKPADDAGLV) of a protein found in human gastric juice, as an anti-ulcer agent stable in gastric juice and without reported toxicity in the models used. It gathers the group's rodent work on lesions of the periodontium, oesophagus, stomach, duodenum, intestine, liver and pancreas, with particular attention to alcohol- and NSAID-induced injury and to adjuvant arthritis. In rat oesophagitis the peptide restored pressure in the lower oesophageal and pyloric sphincters. It is described as angiogenic, protective of endothelium, active against thrombus formation, involved with the nitric-oxide system, a scavenger of free radicals and neuroprotective, and as closing gastrocutaneous, duodenocutaneous and colocutaneous fistulas and intestinal anastomoses in rats.

Study design

Review of BPC 157 in gastrointestinal models, written by the Zagreb group that originated the compound.

What it does not show

Nearly all of the cited work is rodent research from the reviewing group itself. The review mentions safety in inflammatory-bowel-disease trials, but those trials are not reported in detail here or in a peer-reviewed efficacy paper.

A review summarises other papers and inherits every limit of the work it cites. It adds no new experiment, and where a review is written by the group that developed the compound, the selection of what to include is theirs.

Where this paper is cited

  • BPC-157 — Review of BPC 157 in gastrointestinal-tract injury models, including ulcer, fistula and anastomosis healing in rodents.

Other papers cited for BPC-157

Further reading

How this page was made: the citation was retrieved from PubMed by PMID and checked against the title on the product page; the summary was written from the paper's abstract and reports only what the abstract reports. Read the paper itself before relying on any figure here.

Research use only This page summarises a published paper. It is not a claim that any product sold by Zyrna Research does what the paper describes, and nothing here is dosing guidance. Nothing sold by Zyrna Research is for human or veterinary use.